Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.71 |
| ▸ | KMO | O15229 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 12/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10614755 | 0.88 | KMO (0.62) | HSP90AA1KMOMEN1KMT2AHAO1 | |
| SCHEMBL12260895 | 0.86 | HSP90AA1 (0.57) | HSP90AA1KMOMEN1KMT2AHAO1 | |
| SCHEMBL9445013 | 0.86 | HSP90AA1 (0.68) | HSP90AA1KMOMEN1KMT2AHAO1 | |
| SCHEMBL2090029 | 0.86 | HSP90AA1 (0.57) | HSP90AA1KMOMEN1KMT2AHAO1 | |
| SCHEMBL10354976 | 0.86 | HSP90AA1 (0.57) | HSP90AA1KMOMEN1KMT2AHAO1 | |
| SCHEMBL10354980 | 0.86 | HSP90AA1 (0.74) | HSP90AA1KMOMEN1KMT2AHAO1 | |
| SCHEMBL257844 | 0.86 | HSP90AA1 (0.57) | HSP90AA1KMOMEN1KMT2AHAO1 | |
| SCHEMBL632533 | 0.86 | MAOA (0.61) | HSP90AA1KMOMEN1KMT2ASLC6A4 | |
| SCHEMBL14649910 | 0.86 | HSP90AA1 (0.57) | HSP90AA1KMOMEN1KMT2AHAO1 | |
| SCHEMBL11175966 | 0.86 | HSP90AA1 (0.57) | HSP90AA1KMOMEN1KMT2AHAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117177989-A | Activity-inducible fusion proteins with heat shock protein 90 binding domain | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 2023-12-05 | — | — | CN | disclosed |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RES INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230172981-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-06-08 | — | — | US | disclosed |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | SEATTLE CHILDREN'S HOSPITAL (US) | 2023-05-16 | — | — | US | disclosed |
| US-20200087399-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | PHOSPHO1, LCAT, CD47 | HSP90AA1 3287/4885KMO 3514/4885MEN1 2203/4885 |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | HSP90AA1 3287/4885KMO 3514/4885MEN1 2203/4885 |
| US-20200087399-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | HSP90AA1 3287/4885KMO 3514/4885MEN1 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.